Human amnion-derived cells as a reliable source of stem cells

Current Molecular Medicine

Volumn 12, Issue 10, 2012, Pages 1340-1349

  Saito, S ^a,b,c,d   Lin, Y C ^b   Murayama, Y ^c   Hashimoto, K ^e   Yokoyama, K K ^a,b,f,g  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NIHON UNIVERSITY   (Japan)

^d Saito Laboratory of Cell Technology   (Japan)

^e TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^f RIKEN BIORESOURCE CENTER   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

Amnion; ES cells; IPS cells; Pluripotent stem cells; Reprogramming; Transcription factors

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ENDOGLIN; GLIAL FIBRILLARY ACIDIC PROTEIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; MYOSIN LIGHT CHAIN 2; NEURON SPECIFIC ENOLASE; OCTAMER TRANSCRIPTION FACTOR 4; RETROVIRUS VECTOR; STAGE SPECIFIC EMBRYO ANTIGEN 1; STAGE SPECIFIC EMBRYO ANTIGEN 3; STAGE SPECIFIC EMBRYO ANTIGEN 4; THY 1 ANTIGEN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR SOX2;

AMNION CELL; ARTICLE; CELL DIFFERENTIATION; CELL RENEWAL; CELL TRANSFORMATION; CLONOGENIC ASSAY; ELECTROPORATION; EMBRYONIC STEM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GERM LAYER; HEART MUSCLE CELL; HUMAN; LIVER CELL; MULTIPOTENT STEM CELL; NERVE CELL; NEURAL STEM CELL; NEUROLOGIC DISEASE; NONHUMAN; OSTEOBLAST; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; STEM CELL; TERATOMA;

AMNION; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HEPATOCYTES; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MULTIPOTENT STEM CELLS; MYOCYTES, CARDIAC; OCTAMER TRANSCRIPTION FACTOR-3; OSTEOBLASTS; REGENERATION; SOXB1 TRANSCRIPTION FACTORS; STAGE-SPECIFIC EMBRYONIC ANTIGENS;

EID: 84870183737     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412803833625     Document Type: Article

References (96)

1. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschläger M. Oct4-expressing cells in human amniotic fluid: a new source for stem cell research? Hum Reprod 2003; 18: 1489-1493.
2. Tamagawa T, Ishiwata I, Saito S. Establishment and characterization of pluripotent stem cell line derived from human amniotic membranes and induction of germ layers in vitro. Hum Cell 2004; 17: 125-130.
3. Miki T, Lehman T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells 2005; 23: 1549-1559.
4. Saito S, Yokoyama K, Tamagawa T, Ishiwata I. Derivation and induction of the differentiation of animal ES cells as well as human pluripotent stem cells from fetal membrane. Hum Cell 2005; 18: 135-141.
5. De Coppi P, Bartsch G Jr, Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25: 100-106.
6. Billic G, Zeisberger SM, Mallik AS, Zimmermann R, Zisch AH. Comparative characterization of cultured human term epithelial and mesenchymal stromal cells for application in cell therapy. Cell Transplant 2008; 17: 955-968.
7. Carraro G, Perin L, Sedrakyan S, et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 2008; 26: 2902-2911.
8. Tamagawa T, Ishiwata I, Ishikawa H, Nakamura Y. Induced in vitro differentiation of neural-like cells from human amnionderived fibroblast-like cells. Hum Cell 2008; 21: 38-45.
9. Mareschi K, Rusttichelli D, Comunanza V, et al. Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with functional voltage-gated sodium channels. Cytotherapy 2009; 11: 534-547.
10. Walther G, Gekas J, Bertrand OF. Amniotic stem cells for cellular cardiomyoplasty: promises and premises. Catheter Cardiovasc Interv 2009; 73, 917-924.
11. Díaz-Prado S, Muiños-López E, Hermida-Gómez T, et al. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. Differentiation 2011; 81: 162-171.
12. Miki T. Amnion- derived stem cells: in quest of clinical applications. Stem Cell Res & Therapy 2011; 2: 25-35.
13. Tylki-Szymańska A, Maciejko D, Kidawa M, Jabłońska-Budaj U, Czartoryska B. Amniotic tissue transplantation as a tool of treatment in some lysosomal storage diseases. J Inherit Metabol Disease 1985; 8: 101-104.
14. Yeager AM., Singer HS, Buck JR., et al. A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. Am J Med Genet 1985; 22: 347-355.
15. Scaggiante B, Pineschi A, Sustersich M, Andolina M, Agosti E, Romeo D. Successful therapy of Niemann-Pick disease by implantation of human amniotic membrane. Transplantation 1987; 44: 59-61.
16. Sakuragawa N, Yoshikawa A, Sasaki M. Amniotic tissue transplantation: clinical and biochemical evaluations for some lysosomal storage diseases. Brain Dev 1992; 14: 7-11.
17. Sakuragawa N, Thangavel R., Mizuguchi M, Hirasawa M, Kamo I. Expression markers for both neural and glial cells in human amniotic epithelial cells. Neurosci Lett 1996; 209: 9-12.
18. Gardner RL. Origin and differentiation of extraembryonic tissues in the mouse. Int Rev Exp Pathol 1983; 24: 63-133.
19. Rossant J. Development of extraembryonic lineages. Seminer Cell Develop Biol 1995; 6: 237-247.
20. Evans MJ, Kaufman MH. Establishment in culture of pluripotent cells from mouse embryos. Nature 1981; 292: 154-156.
21. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981; 78: 7634-7638.
22. Hatami M, Mehrjarardi NZ, Kiani S, et al. Human embryonic stem cell-derived neural precursor transplants in collagen scaffolds promote recovery in injured rat spinal cord. Cytotherapy 2009; 11: 618-630.
23. Sharp J, Frame J, Siegenthaler M, Nistor G, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells 2010; 28: 152-163.
24. Geeta R, Ramnath RL, Rhao HS, Chandra V. One year survival and significant reversal of mortor deficits in Parkinsonian rats transplanted with hES derived dopaminergic neurons. Biochem Biophys Res Commun 208; 373: 258-264.
25. Jiang J, Au M, Lu K, et al. Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells 2007; 25: 1940-1953.
26. Pal R. Embryonic stem (ES) cell-derived cardiomyocytes: a good candidate for cell therapy applications. Cell Biol Int 2009; 33: 325-336.
27. Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ. Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci USA 2005; 102: 19081-19086.
28. Clarke DL, Clas BJ, Wilbertz J, et al. Generalized potential of adult neural stem cells. Science 2000; 288: 1660-1663.
29. Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000; 61: 364-370.
30. Matsui Y, Zsebo K, Hogan BL. Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture. Cell 1992; 70: 841-847.
31. Kanatsu-Shinohara M, Inoue K, Lee J, et al. Generation of pluripotent stem cells from neonatal mouse testis. Cell 2004; 119: 1001-1012.
32. Guan K, Nayernia K, Maier LS, et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 2006; 440: 1199-1203.
33. Brons IG, Smithers LE, Trotten MW, et al. Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature 2007; 448: 191-195.
34. Tesar P, Chenoweth JG, Brook FA, et al. New lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007; 448: 196-199.
35. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3: 595-605.
36. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
37. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
38. Okita K, Ichikawa T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature 2007; 448: 313-317.
39. Meissner A, Wearing M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007; 25: 1177-1181.
40. Maherali N, Ahfeld T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008; 3: 340-345.
41. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms and applications. Gen Develop 2010; 24: 2239-2263.
42. Okita K, Nakagawa M, Hynjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-953.
43. Saito S, Wang SW, Ku CC, et al. Human amnion-derived pluripotent stem cells as a promising source for regenerative medicine and tissue engineering. J Bioeng Biomed Sci 2011; doi: 10.4172/2155- 9538. S2-005.
44. Li C, Zhou J, Shi G, et al. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum Mol Genet 2009; 18: 4340-4349.
45. Wolfrum K, Wang Y, Prigione A, Sperling K, Lehrach H, Adjaye J. The large principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid- derived human iPS cells. PLoS One 2010, 5: e13703.
46. Zhao HX, Li Y, Jin HF, et al. Rapid and efficient reprogramming of human amnion-derived cells into pluripotency by three factors Oct4/Sox2/Nanog. Differentiation 2010; 80: 123-129.
47. Nichols J, Zevnik B, Anastasiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95: 379-391.
48. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-655.
49. Hay DC, Sutherland L, Clark J, Burdon T. Oct4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 2004; 22: 225-235.
50. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
51. Loh YH, Wu Q, Chew JL, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006; 38: 431-440.
52. Xu RH, Sampsell-Barron TL, Gu F, et al. Nanog is a direct target of TGFß/activin-mediated SMAD signaling in human ES cells. Cell Stem Cell 2009; 3: 196-206.
53. Elwan MA, Sakuragawa N. Evidence for synthesis and release of catecholamines by human amniotic epithelial cells. Neuroreport 1997; 8: 3435-3438.
54. Kakishita K, Elvan MA, Nakao N, Itakura T, Sakuragawa N. Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of Parkinson's disease: a potential source of donor for transplantation therapy. Exp Neurol 2000; 165: 27-34.
55. Kadner A, Zund G, Maurus C, et al. Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothor Surg 2002; 25: 635-641.
56. Breymann C, Schmidt D, Hoerstrup SP. Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev 2006; 2: 87-92.
57. Compard D, Lysy PA, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 2008; 134: 833-848.
58. Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Ageing Dev 2001; 122: 713-734.
59. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res 2008; 314: 1937-1944.
60. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008; 129: 163-1673.
61. Niwa H. How is pluripotency determined and maintained? Development 2007; 134: 635-646.
62. Thomson M, Liu SJ, Zou LN, Smith Z, Meissner A, Ramanathan S. Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell 2011; 145: 875-889.
63. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced adult neural stem cells by reprogramming with two factors. Nature 2008; 454: 646-650.
64. Kim JB, Sebastiano V, Wu G, et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009; 136: 411-419.
65. Ying QL, Nicols J, Chambers I, Smith A. BMP induction of Id proteins suppress differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003; 115: 281-292.
66. Ying QL, Wray J, Nicols J, et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453: 519-523.
67. Hanna J, Cheng AW, Saha K, et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci USA 2010; 107: 9222-9227.
68. Deheron L, Opitz SL, Zaehres H, et al. LIF/STAT3 signaling fails to maintain self- renewal of human embryonic stem cells. Stem Cells 2004; 22: 770-778.
69. Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using Oct4 and Sox2. Cell Stem Cells 2009; 5: 353-357.
70. Aoki T, Ohnishi H, Oda Y, et al. Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-Myc. Tissue Eng Part A 2010; 16: 2197-2206.
71. Huangfu D, Maeker R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by smallmolecule compounds. Nat Biotechnol 2008; 26: 795-797.
72. Huangufu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
73. Lin T, Ambasudhan R, Yuan X, et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009; 6: 805-808.
74. Ivanova N, Dobrin R, Lu R, et al. Dissecting self-renewal in stem cells with RNA interference. Nature 2006; 442: 533-538.
75. Masui S, Nakatake Y, Toyooka Y, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Biotechnol 2007; 9: 625-635.
76. Clark AT. The stem cell identify of testicular cancer. Stem Cell Rev 2007; 3: 49-59.
77. Gu G, Yuan J, Willis M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 4: 361-370.
78. Huang YC, Saito S, Yokoyama KK. Histone chaperone Jun Dimerization Protein2 (JDP2): role in cellular senescence and aging. Kaohsiung J Med Sci 2010; 26: 515-531.
79. Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460: 1145-1148.
80. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumor suppressor pathway to somatic cell reprogramming. Nature 2009; 460: 1140-1144.
81. Hong H, Takahashi K, Ichida T, et al. Suppression of induced pluripotent stem cell generation by the p51-p21 pathway. Nature 2009; 460: 1132-1135.
82. Sarig R, Rivlin N, Brosh R, et al. Mutant p53 facilitate somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010; 207: 2127-2140.
83. Zeng H, Ying H, Yang H, et al. P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455: 1129-1133.
84. Tang C, Lee AS, Volker JP, et al. An antibody against SSEA- 5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 2011; 29: 829-834.
85. Akutsu H, Cowan A, Melton D. Human embryonic stem cells. Methods Enzymol 2006; 418: 78-92.
86. Amit M, Itskoviz-Eldor J. Maintenance of human embryonic stem cells in animal serum-and feeder layer-free culture conditions. Methods Mol Biol 2006; 331: 105-113.
87. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185-187.
88. Stewart MH, Bendall SC, Bhatia M. Deconstructing human embryonic stem cell cultures: niche regulation of self-renewal and pluripotency. J Mol Med 2008; 86: 875-886.
89. Babaie Y, Herwig R, Greber B, et al. Analysis of Oct4- dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cell 2007; 25: 500-510.
90. Rossant J. Stem cells and early lineage development. Cell 2008; 132: 527-531.
91. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000; 18: 399-404.
92. Nicols J, Smith A. Naïve and primed pluripotent states. Cell Stem Cell 2009; 4: 487-492.
93. Han DW, Greber B, Wu G, et al. Direct reprogramming of fibroblasts into epiblast stem cells. Nat Biotechnol 2011; 13: 666-671.
94. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143: 508-525.
95. Hanna J, Wearing M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920-1923.
96. Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009; 5: 584-595.